Tumor-Specific T Cell Activation in Malignant Brain Tumors
Due to their delicate locations as well as aggressive and infiltrative behavior, malignant brain tumors remain a therapeutic challenge. Harnessing the efficacy and specificity of the T-cell response to counteract malignant brain tumor progression and recurrence, represents an attractive treatment op...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00205/full |
| _version_ | 1819145885612769280 |
|---|---|
| author | Malte Mohme Marian Christoph Neidert Marian Christoph Neidert Marian Christoph Neidert |
| author_facet | Malte Mohme Marian Christoph Neidert Marian Christoph Neidert Marian Christoph Neidert |
| author_sort | Malte Mohme |
| collection | DOAJ |
| description | Due to their delicate locations as well as aggressive and infiltrative behavior, malignant brain tumors remain a therapeutic challenge. Harnessing the efficacy and specificity of the T-cell response to counteract malignant brain tumor progression and recurrence, represents an attractive treatment option. With the tremendous advances in the current era of immunotherapy, ongoing studies aim to determine the best treatment strategies for mounting a tumor-specific immune response against malignant brain tumors. However, immunosuppression in the local tumor environment, molecular and cellular heterogeneity as well as a lack of suitable targets for tumor-specific vaccination impede the successful implementation of immunotherapeutic treatment strategies in neuro-oncology. In this review, we therefore discuss the role of T cell exhaustion, the genetic and antigenic landscape, potential pitfalls and ongoing efforts to overcome the individual challenges in order to elicit a tumor-specific T cell response. |
| first_indexed | 2024-12-22T13:05:08Z |
| format | Article |
| id | doaj.art-b8b4df596f7a44fa9df0fff3513dac64 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T13:05:08Z |
| publishDate | 2020-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b8b4df596f7a44fa9df0fff3513dac642022-12-21T18:24:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-02-011110.3389/fimmu.2020.00205514216Tumor-Specific T Cell Activation in Malignant Brain TumorsMalte Mohme0Marian Christoph Neidert1Marian Christoph Neidert2Marian Christoph Neidert3Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesBroad Institute of Harvard and MIT, Cambridge, MA, United StatesDue to their delicate locations as well as aggressive and infiltrative behavior, malignant brain tumors remain a therapeutic challenge. Harnessing the efficacy and specificity of the T-cell response to counteract malignant brain tumor progression and recurrence, represents an attractive treatment option. With the tremendous advances in the current era of immunotherapy, ongoing studies aim to determine the best treatment strategies for mounting a tumor-specific immune response against malignant brain tumors. However, immunosuppression in the local tumor environment, molecular and cellular heterogeneity as well as a lack of suitable targets for tumor-specific vaccination impede the successful implementation of immunotherapeutic treatment strategies in neuro-oncology. In this review, we therefore discuss the role of T cell exhaustion, the genetic and antigenic landscape, potential pitfalls and ongoing efforts to overcome the individual challenges in order to elicit a tumor-specific T cell response.https://www.frontiersin.org/article/10.3389/fimmu.2020.00205/fullimmunityT cellsglioblastomagliomavaccinetumor-specific |
| spellingShingle | Malte Mohme Marian Christoph Neidert Marian Christoph Neidert Marian Christoph Neidert Tumor-Specific T Cell Activation in Malignant Brain Tumors Frontiers in Immunology immunity T cells glioblastoma glioma vaccine tumor-specific |
| title | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| title_full | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| title_fullStr | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| title_full_unstemmed | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| title_short | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| title_sort | tumor specific t cell activation in malignant brain tumors |
| topic | immunity T cells glioblastoma glioma vaccine tumor-specific |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.00205/full |
| work_keys_str_mv | AT maltemohme tumorspecifictcellactivationinmalignantbraintumors AT marianchristophneidert tumorspecifictcellactivationinmalignantbraintumors AT marianchristophneidert tumorspecifictcellactivationinmalignantbraintumors AT marianchristophneidert tumorspecifictcellactivationinmalignantbraintumors |